Track market-moving stories before they get noisy

In the latest trading session, Veeva Systems (VEEV - Free Report) closed at $179.58, marking a -2.69% move from the previous day. This move lagged the S&P 500's daily loss of 1.21%. Elsewhere, the Dow lost 0.97%, while the tech-heavy Nasdaq lost 2.15%.

The provider of cloud-based software services for the life sciences industry's stock has climbed by 14.38% in the past month, exceeding the Medical sector's gain of 3.97% and the S&P 500's gain of 0.42%.

Market participants will be closely following the financial results of Veeva Systems in its upcoming release. In that report, analysts expect Veeva Systems to post earnings of $2.22 per share. This would mark year-over-year growth of 11.56%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $904.07 million, up 14.57% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $9.05 per share and a revenue of $3.64 billion, demonstrating changes of +11.73% and +13.96%, respectively, from the preceding year.

It is also important to note the recent changes to analyst estimates for Veeva Systems. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Veeva Systems currently has a Zacks Rank of #3 (Hold).

In terms of valuation, Veeva Systems is currently trading at a Forward P/E ratio of 20.4. For comparison, its industry has an average Forward P/E of 26.45, which means Veeva Systems is trading at a discount to the group.

Investors should also note that VEEV has a PEG ratio of 0.58 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Info Systems industry had an average PEG ratio of 2.89 as trading concluded yesterday.

The Medical Info Systems industry is part of the Medical sector. With its current Zacks Industry Rank of 76, this industry ranks in the top 31% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Veeva Systems (VEEV - Free Report) .

Veeva currently has an average brokerage recommendation (ABR) of 1.88, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 26 brokerage firms. An ABR of 1.88 approximates between Strong Buy and Buy.

Of the 26 recommendations that derive the current ABR, 14 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 53.9% and 11.5% of all recommendations.

Brokerage Recommendation Trends for VEEV

Check price target & stock forecast for Veeva here>>>

While the ABR calls for buying Veeva, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is VEEV a Good Investment?In terms of earnings estimate revisions for Veeva, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $9.05.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Veeva. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Veeva.

Posted by Defense World Staff on Jul 22nd, 2026

Andra AP fonden trimmed its holdings in Veeva Systems Inc. (NYSE:VEEV – Free Report) by 27.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,917 shares of the technology company’s stock after selling 32,100 shares during the period. Andra AP fonden owned approximately 0.05% of Veeva Systems worth $14,565,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Principal Financial Group Inc. raised its stake in shares of Veeva Systems by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company’s stock valued at $727,513,000 after purchasing an additional 271,252 shares during the period. State Street Corp boosted its position in shares of Veeva Systems by 2.4% in the fourth quarter. State Street Corp now owns 3,589,425 shares of the technology company’s stock valued at $801,267,000 after acquiring an additional 85,695 shares during the period. Geode Capital Management LLC boosted its position in shares of Veeva Systems by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 3,172,716 shares of the technology company’s stock valued at $706,442,000 after acquiring an additional 23,117 shares during the period. AQR Capital Management LLC grew its stake in Veeva Systems by 31.2% during the third quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company’s stock valued at $706,078,000 after acquiring an additional 574,164 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Veeva Systems by 12.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,728,089 shares of the technology company’s stock worth $385,761,000 after acquiring an additional 189,093 shares during the period. Institutional investors own 88.20% of the company’s stock.

Wall Street Analyst Weigh In VEEV has been the subject of several analyst reports. Evercore reissued an “outperform” rating and issued a $185.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Canaccord Genuity Group lowered their price objective on Veeva Systems from $235.00 to $220.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Oppenheimer restated an “outperform” rating on shares of Veeva Systems in a research note on Monday. BTIG Research reaffirmed a “buy” rating and issued a $340.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Finally, TD Cowen reissued a “buy” rating on shares of Veeva Systems in a report on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $247.74.

Get Our Latest Report on Veeva Systems

Insider Buying and Selling at Veeva Systems In other news, Director Priscilla Hung sold 750 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $155.64, for a total value of $116,730.00. Following the completion of the sale, the director owned 3,253 shares of the company’s stock, valued at approximately $506,296.92. The trade was a 18.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.60% of the company’s stock.

Veeva Systems Price Performance Shares of NYSE VEEV opened at $189.46 on Wednesday. The stock has a market capitalization of $30.78 billion, a P/E ratio of 33.77, a PEG ratio of 0.85 and a beta of 0.94. Veeva Systems Inc. has a one year low of $148.05 and a one year high of $310.50. The firm’s 50 day simple moving average is $173.03 and its two-hundred day simple moving average is $182.13.

Veeva Systems (NYSE:VEEV – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The technology company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The firm had revenue of $882.95 million during the quarter, compared to analyst estimates of $857.73 million. During the same period in the previous year, the business posted $1.97 EPS. The business’s quarterly revenue was up 16.3% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. As a group, equities analysts expect that Veeva Systems Inc. will post 6.65 earnings per share for the current fiscal year.

About Veeva Systems (Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

Read More Five stocks we like better than Veeva Systems Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV – Free Report).

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINENetApp, Inc. $NTAP Shares Sold by California Public Employees Retirement System

NEXT HEADLINE »Alesco Advisors LLC An ESL Co Takes $713,000 Position in ServiceNow, Inc. $NOW

Veeva Systems (VEEV - Free Report) ended the recent trading session at $193.09, demonstrating a -1.89% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.38%. Elsewhere, the Dow saw an upswing of 0.02%, while the tech-heavy Nasdaq appreciated by 0.9%.

The stock of provider of cloud-based software services for the life sciences industry has risen by 21.36% in the past month, leading the Medical sector's gain of 4.34% and the S&P 500's gain of 1.27%.

Investors will be eagerly watching for the performance of Veeva Systems in its upcoming earnings disclosure. On that day, Veeva Systems is projected to report earnings of $2.22 per share, which would represent year-over-year growth of 11.56%. Alongside, our most recent consensus estimate is anticipating revenue of $904.07 million, indicating a 14.57% upward movement from the same quarter last year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $9.05 per share and a revenue of $3.64 billion, indicating changes of +11.73% and +13.96%, respectively, from the former year.

Investors might also notice recent changes to analyst estimates for Veeva Systems. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, Veeva Systems is carrying a Zacks Rank of #3 (Hold).

Digging into valuation, Veeva Systems currently has a Forward P/E ratio of 21.75. This signifies a discount in comparison to the average Forward P/E of 28.61 for its industry.

Also, we should mention that VEEV has a PEG ratio of 0.62. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical Info Systems industry had an average PEG ratio of 3.19 as trading concluded yesterday.

The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Veeva Systems (VEEV - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this provider of cloud-based software services for the life sciences industry have returned +14.7% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical Info Systems industry, to which Veeva belongs, has gained 17.8% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Veeva is expected to post earnings of $2.22 per share for the current quarter, representing a year-over-year change of +11.6%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $9.05 for the current fiscal year indicates a year-over-year change of +11.7%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $9.9 indicates a change of +9.4% from what Veeva is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Veeva.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Veeva, the consensus sales estimate of $904.07 million for the current quarter points to a year-over-year change of +14.6%. The $3.64 billion and $4.07 billion estimates for the current and next fiscal years indicate changes of +14% and +11.7%, respectively.

Last Reported Results and Surprise HistoryVeeva reported revenues of $882.95 million in the last reported quarter, representing a year-over-year change of +16.3%. EPS of $2.24 for the same period compares with $1.97 a year ago.

Compared to the Zacks Consensus Estimate of $857.33 million, the reported revenues represent a surprise of +2.99%. The EPS surprise was +5.16%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Veeva is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Veeva. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

It has been about a month since the last earnings report for Veeva Systems (VEEV - Free Report) . Shares have added about 7.9% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Veeva due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Veeva Systems Q1 Earnings & Revenues Beat, Operating Margin RiseVeeva Systems reported adjusted earnings per share of $2.24 for the first quarter of fiscal 2027, which increased 13.7% from the year-ago figure of $1.74. Adjusted earnings per share beat the Zacks Consensus Estimate by 5.2%.

GAAP earnings per share in the fiscal first quarter was $1.57, up 14.6% from the year-ago period’s $1.37.

VEEV’s Q1 Revenue DetailsIn the quarter under review, the company’s revenues totaled $882.9 million, beating the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the top line improved 16.3%.

The fiscal first-quarter top line was driven by Veeva Systems’ robust segmental performance.

Segmental Analysis of VEEVVeeva Systems derives revenues from two operating segments: Subscription services and Professional services and other.

In the fiscal first quarter, Subscription services revenues improved 15% from the year-ago quarter to $730.2 million. Per management, this uptick was driven by both its established and newer solutions.

Professional services and other revenues increased 22.9% year over year to $152.8 million.

Q1 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit improved 13.1% year over year to $662 million. However, the gross margin contracted 220 basis points (bps) to 74.9%.

Sales and marketing expenses increased 12.7% year over year to $111.1 million. Research and development (R&D) expenses rose 13.2% year over year to $208.3 million, while general and administrative expenses increased 0.9% year over year to $69.5 million. Total operating expenses of $388.9 million increased 10.6% year over year.

Operating profit totaled $273.1 million, which increased 16.8% from the prior-year quarter. The operating margin in the fiscal first quarter expanded 20 bps to 30.9%.

VEEV’s Financial PositionThe company exited first-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.31 billion compared with $6.56 billion at the fiscal fourth quarter of 2026-end.

Net cash provided by operating activities at the end of the quarter was $1.13 billion compared with $877.2 million a year ago.

Q2 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the fiscal second quarter and fiscal 2027.

For the fiscal second quarter, the company expects total revenues between $902 million and $905 million. The Zacks Consensus Estimate is currently pegged at $886.8 million.

Subscription revenues are estimated to be approximately $754 million, and revenues for Professional services and other are expected to be in the range of $148-$151 million for the fiscal second quarter.

For the fiscal second quarter, adjusted earnings per share is anticipated to be between $2.21 and $2.22. The Zacks Consensus Estimate is pegged at $2.19.

Veeva Systems now expects revenues for fiscal 2027 between $3,635 million and $3,645 million. The Zacks Consensus Estimate is currently pegged at $3.59 billion.

For fiscal 2027, Subscription revenues are now expected to be approximately $3,060 million. This consists of Commercial Solutions’ subscription revenues of around $1,395 million and R&D Solutions’ subscription revenues of approximately $1,665 million.

Professional services and other revenues for fiscal 2027 are now expected to be between $575 million and $580 million.

Adjusted earnings per share for fiscal 2027 is now expected to be approximately $9.05. The Zacks Consensus Estimate is pegged at $8.86.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

VGM ScoresAt this time, Veeva has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Veeva has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Key Takeaways VEEV acquired Copli and launched Falcon MLR to automate life sciences content reviews.Falcon MLR integrates with PromoMats to check content against labels and country rules.VEEV says Falcon MLR could eliminate over 70% of manual MLR labor in five years. Veeva Systems (VEEV - Free Report) has strengthened its artificial intelligence (AI)-driven commercial content capabilities with the acquisition of Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Alongside the acquisition, the company launched Veeva Falcon MLR, an AI-powered solution designed to accelerate content review and approval processes.

From an investor's standpoint, the acquisition expands Veeva's AI portfolio and enhances the value proposition of its commercial cloud offerings. By embedding agentic automation into the MLR workflow, the company is likely to drive stronger customer adoption, deepen platform stickiness and create additional cross-selling opportunities, which could support long-term revenue growth and strengthen its competitive position in the life sciences software market.

Likely Trend of VEEV Stock Following the NewsShares of VEEV have traded flat since the announcement on June 23. In the year-to-date period, shares of the company lost 23.3% compared with the industry’s 10.9% decline.  The S&P 500 increased 7.1% in the same time frame.

The launch of Veeva Falcon MLR is expected to strengthen Veeva's long-term growth prospects by expanding its AI-driven product portfolio and increasing the strategic value of its Commercial Cloud platform. As pharmaceutical and biotechnology companies seek to accelerate content approvals while maintaining regulatory compliance, Falcon MLR can help streamline one of the industry's most time-consuming workflows through agentic automation.

Its seamless integration with Veeva PromoMats is likely to drive broader customer adoption, improve client retention and create cross-selling opportunities across Veeva's installed base, reinforcing recurring subscription revenues and the company's leadership in life sciences software.

VEEV currently has a market capitalization of $27.84 billion.

Image Source: Zacks Investment Research

More on the NewsVeeva Falcon MLR is an agentic MLR solution that automates the review of promotional and medical content for life sciences companies. Built on Copli's technology and integrated with Veeva PromoMats, the solution conducts compliance checks against approved product labels and country-specific regulations, enabling marketing teams, MLR reviewers and agencies to streamline the review and approval process. According to Veeva, Falcon MLR has the potential to eliminate more than 70% of manual MLR labor over the next five years, significantly shortening review cycles while improving operational efficiency.

The launch is expected to primarily strengthen Veeva's Commercial Cloud business, particularly its Content Management portfolio led by PromoMats. PromoMats is widely used by pharmaceutical and biotechnology companies to manage the creation, review, approval and distribution of compliant promotional content. By embedding agentic AI directly into this workflow, Veeva enhances the functionality of an already mission-critical application, increasing customer value while making its commercial content ecosystem more intelligent and difficult to replace. The addition of Falcon MLR also complements Veeva's broader Falcon AI portfolio, reinforcing the company's strategy of integrating AI capabilities across its cloud applications.

The acquisition of Copli further expands Veeva's AI expertise and accelerates the commercialization of agentic automation across the life sciences industry. As demand for AI-powered compliance and content management solutions continues to rise, Falcon MLR positions Veeva to capture incremental growth opportunities while strengthening its competitive moat in life sciences software.

Favorable Industry Prospect for VEEVPer a report by Grand View Research, the global agentic AI in healthcare market size was estimated at $538.51 million in 2024 and is projected to reach $4.96 billion by 2030, expanding at a CAGR of 45.56%.

The rising automation of repetitive tasks, growing focus on cost and resource optimization, and increasing adoption of enhanced patient care solutions are factors contributing to market growth. 

A Recent Development by VEEVRecently, VEEV announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness.

Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Key Takeaways Veeva launched EHS within Quality Cloud to help sites manage operational and environmental risks.VEEV shares fell 2% after the news, with the stock down 29.2% year to date.Veeva EHS automates incident reporting, investigations and compliance workflows on one platform. Veeva Systems (VEEV - Free Report) recently announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness.

Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution. The company believes organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention.

Veeva EHS is expected to be available to early adopters in August 2026.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, VEEV shares lost 2% at yesterday’s closing. Year to date, the stock has declined 29.2%, underperforming the industry’s 15.2% fall and the S&P 500’s 7.3% rise.

The launch of Veeva EHS is expected to strengthen Veeva’s position in the EHS software market by expanding its Quality Cloud portfolio. The unified platform can drive higher customer adoption, improve cross-selling opportunities and increase recurring revenues. Its automation, real-time risk visibility and integrated compliance capabilities also enhance Veeva's competitive advantage over legacy EHS solution providers, supporting long-term business growth.

VEEV currently has a market capitalization of $26.21 billion.

Image Source: Zacks Investment Research

More on Veeva EHSVeeva EHS enables organizations to report safety incidents in real time, manage investigations from start to finish and automate compliance workflows within a single platform. The solution integrates with Veeva QMS and Veeva Training, allowing safety events to automatically create quality deviations and assign relevant training. This eliminates duplicate data entry, streamlines workflows and helps organizations maintain compliance.

According to Bobbie Grant, Global Senior EHS Manager at Thermo Fisher Scientific, a modern EHS platform with unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency. Grant added that Veeva provides an advanced solution that can maintain data integrity and provide the foundation for AI-driven capabilities to reduce risk over time.

Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the environmental health and safety (EHS) software market is valued at $8.9 billion in 2026 and is expected to witness a CAGR of 8.1% through 2030.

Factors like the stringent regulatory requirements that healthcare and life science organizations must navigate, digital transformation initiatives in healthcare and life sciences, a growing focus on workplace safety and risk reduction, and the integration of AI and machine learning are boosting the market’s growth.

Other NewsVeeva recently acquired Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Copli is available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insights and streamlined workflows

, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva EHS, a new application in Veeva Quality Cloud for environmental, health, and safety. With Veeva EHS, manufacturing and testing sites can proactively identify, manage, and mitigate operational and environmental risks and ensure global compliance readiness.

"A modern EHS solution that simplifies processes through unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency," said Bobbie Grant, global senior EHS manager, Thermo Fisher Scientific. "It is exciting to see Veeva build an advanced solution that can not only maintain data integrity today but also provide the foundation for AI-driven capabilities that can further reduce risk over time."

Veeva EHS will provide an intuitive way to report safety incidents on the spot and manage investigations from start to finish. Because it connects directly with Veeva QMS and Veeva Training, a safety event can automatically trigger a quality deviation and assign targeted retraining, eliminating duplicate data entry and ensuring compliance.

"Delivering an advanced, automated approach to managing environmental, health, and safety processes, Veeva EHS will free up time for EHS teams and ensure quick and accurate execution," said Beth Tanner, vice president, Veeva EHS strategy. "Organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention."

Planned for early adopter availability in August 2026, Veeva EHS marks a significant step in how organizations manage environmental, health, and safety responsibilities with increased transparency and intelligent automation.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
[email protected]

SOURCE Veeva Systems

719 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Veeva Systems (VEEV - Free Report) reported $882.95 million in revenue for the quarter ended April 2026, representing a year-over-year increase of 16.3%. EPS of $2.24 for the same period compares to $1.97 a year ago.

The reported revenue represents a surprise of +2.99% over the Zacks Consensus Estimate of $857.33 million. With the consensus EPS estimate being $2.13, the EPS surprise was +5.1%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Veeva performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Non-GAAP Gross Margin- Professional services and other: 29.5% versus 27.7% estimated by seven analysts on average.Non-GAAP Gross Margin- Subscription services: 86.8% versus the seven-analyst average estimate of 87%.Revenues- Subscription services: $730.18 million versus $720.28 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +15% change.Revenues- Professional services and other: $152.77 million compared to the $137.05 million average estimate based on seven analysts. The reported number represents a change of +22.9% year over year.Revenues- Professional services and other- Veeva R&D Solutions: $95.2 million versus $88.58 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +22.5% change.Revenues- Subscription services- Veeva R&D Solutions: $392.31 million versus the four-analyst average estimate of $386 million. The reported number represents a year-over-year change of +19.1%.Revenues- Subscription services- Veeva Commercial Solutions: $337.87 million compared to the $334.47 million average estimate based on four analysts. The reported number represents a change of +10.6% year over year.Revenues- Professional services and other- Veeva Commercial Solutions: $57.57 million versus the four-analyst average estimate of $48.72 million. The reported number represents a year-over-year change of +23.6%.View all Key Company Metrics for Veeva here>>>

Shares of Veeva have returned +6.9% over the past month versus the Zacks S&P 500 composite's +5.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Veeva Systems Inc (VEEV) Q1 2027 Earnings Call Highlights: Surpassing Revenue Guidance and Unveiling AI Innovations Veeva Systems Inc (VEEV) reports strong revenue growth and introduces Veeva Falcon, an AI-driven product set to revolutionize drug development processes. Summary

Total Revenue: $883 million for the quarter.Non-GAAP Operating Income: $395 million.

Release Date: June 03, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points Veeva Systems Inc VEEV reported total revenue of $883 million for the quarter, surpassing their guidance.The company introduced Veeva Falcon, a disruptive AI-driven product aimed at automating labor-intensive tasks in drug development.Strong performance in the R&D and Quality Cloud segments, with significant growth potential in early-stage products like eCOA and RTSM.Crossix continues to show robust growth, driven by increased digital spending in the pharma industry and new innovations.The acquisition of Ostro is expected to contribute significantly to commercial subscription revenue, enhancing Veeva's digital engagement capabilities. Negative Points Despite a strong start to the year, Veeva Systems Inc (VEEV) only raised its full-year revenue guidance by $5 million, indicating potential conservatism or unforeseen challenges.The transition to AI applications in pharma is complex, and the full integration of AI into existing systems may take time.There is a risk of cannibalization of traditional SaaS revenue streams as AI-driven solutions like Falcon become more prevalent.The company faces competitive pressure in the CRM space, with ongoing migration decisions among top 20 pharma companies.Veeva Systems Inc (VEEV) is making significant investments in AI and other areas, which could impact short-term margins and profitability. Q & A Highlights Q: Can you expand on Veeva Falcon and its impact on drug development?
A: Peter Gassner, CEO, explained that Falcon represents a new chapter for Veeva, focusing on agentic labor to replace tasks traditionally done by people. Falcon operates at the agent layer, enabling applications to function headlessly. This innovation is disruptive as it introduces AI agents to perform specific tasks, enhancing efficiency in drug development.

Q: How is the pharma industry's appetite for AI applications evolving, and what areas are they focusing on first?
A: Peter Gassner noted that pharma companies are not just transitioning from traditional applications to AI but are adopting a new architecture involving models, agents, and applications. They aim to become agentic biopharmas, allowing AI agents to handle routine tasks, enabling humans to focus on higher-value work.

Q: Can you provide context on the R&D business's strong start and the conservative full-year guidance?
A: Brian Van Wagener, CFO, highlighted that while R&D showed strong growth in Q1, the full-year guidance reflects the early scaling of large products like eCOA and Safety. The business remains healthy, with significant growth potential.

Q: What is driving the strong performance and market share gains for Crossix?
A: Paul Shawah, EVP of Strategy, attributed Crossix's success to the growing digital market and increased pharma spending on digital channels. Crossix is innovating by measuring new channels, which drives market share gains and positions it for durable growth.

Q: How is Veeva pricing Falcon, and which labor roles are being targeted first?
A: Peter Gassner stated that Falcon will likely be priced per document or case, focusing initially on high-volume, repetitive tasks like processing clinical trial documents and safety case triage. These areas are ripe for automation and align with existing outsourcing practices.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Key Takeaways Veeva Systems topped Q1 estimates with revenue up 16.3% and adjusted EPS up 13.7%.VEEV raised fiscal 2027 revenue and adjusted EPS guidance above the consensus estimate.Veeva Systems expanded AI tools, added 27 Vault CRM customers and surpassed 150 live users. Veeva Systems, Inc. (VEEV - Free Report) reported adjusted earnings per share (EPS) of $2.24 for the first quarter of fiscal 2027, which increased 13.7% from the year-ago figure of $1.74. Adjusted EPS beat the Zacks Consensus Estimate by 5.2%.

GAAP EPS in the fiscal first quarter was $1.57, up 14.6% from the year-ago period’s $1.37.

VEEV’s Q1 Revenue DetailsIn the quarter under review, the company’s revenues totaled $882.9 million, beating the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the top line improved 16.3%.

However, shares of the company lost 5.2% in yesterday’s after-market trading. The stock lost 19.8% in the year-to-date period compared with the industry’s decline of 19.1%. However, the S&P 500 Index has increased 10.2% in the same time frame.

The fiscal first-quarter top line was driven by Veeva Systems’ robust segmental performance.

Image Source: Zacks Investment Research

Segmental Analysis of VEEVVeeva Systems derives revenues from two operating segments: Subscription services and Professional services and other.

In the fiscal first quarter, Subscription services revenues improved 15% from the year-ago quarter to $730.2 million. Per management, this uptick was driven by both its established and newer solutions.

Professional services and other revenues increased 22.9% year over year to $152.8 million.

Q1 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit improved 13.1% year over year to $662 million. However, the gross margin contracted 220 basis points (bps) to 74.9%.

Sales and marketing expenses increased 12.7% year over year to $111.1 million. Research and development (R&D) expenses rose 13.2% year over year to $208.3 million, while general and administrative expenses increased 0.9% year over year to $69.5 million. Total operating expenses of $388.9 million increased 10.6% year over year.

Operating profit totaled $273.1 million, which increased 16.8% from the prior-year quarter. The operating margin in the fiscal first quarter expanded 20 bps to 30.9%.

VEEV’s Financial PositionThe company exited first-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.31 billion compared with $6.56 billion at the fiscal fourth quarter of 2026-end.

Net cash provided by operating activities at the end of the quarter was $1.13 billion compared with $877.2 million a year ago.

Q2 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the fiscal second quarter and fiscal 2027.

For the fiscal second quarter, the company expects total revenues between $902 million and $905 million. The Zacks Consensus Estimate is currently pegged at $886.8 million.

Subscription revenues are estimated to be approximately $754 million, and revenues for Professional services and other are expected to be in the range of $148-$151 million for the fiscal second quarter.

For the fiscal second quarter, adjusted EPS is anticipated to be between $2.21 and $2.22. The Zacks Consensus Estimate is pegged at $2.19.

Veeva Systems now expects revenues for fiscal 2027 between $3,635 million and $3,645 million. The Zacks Consensus Estimate is currently pegged at $3.59 billion.

For fiscal 2027, Subscription revenues are now expected to be approximately $3,060 million. This consists of Commercial Solutions’ subscription revenues of around $1,395 million and R&D Solutions’ subscription revenues of approximately $1,665 million.

Professional services and other revenues for fiscal 2027 are now expected to be between $575 million and $580 million.

Adjusted EPS for fiscal 2027 is now expected to be approximately $9.05. The Zacks Consensus Estimate is pegged at $8.86.

Our Take on Veeva Systems’ Q1 ResultsVeeva Systems exited the fiscal first quarter of 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well.

Veeva Systems continues to strengthen its position in life sciences software through rapid innovation in artificial intelligence and expanding customer adoption. During the first quarter, the company significantly advanced its industry-specific AI strategy. Ostro, acquired in March, is now delivering compliant conversational AI for more than 50 brands, while Vault AI remains on track for deployment across all Vault applications in August.

Veeva Systems also introduced Falcon, its new platform designed to provide agentic labor across clinical, regulatory and safety functions, with an early adopter release expected in November. Management believes its deep integration within life sciences workflows and proprietary data assets uniquely positions the company to deliver compliant, high-value AI solutions that enhance productivity and decision-making.        

The company is also leading the transition toward Agentic Commercial. At its Commercial Summit, Veeva Systems outlined a vision for leveraging AI to help biopharma companies improve patient reach and commercial execution. New capabilities, including Agentic Call Report within Vault CRM and Ostro’s conversational AI solutions, are enabling customers to generate and act on commercial evidence more effectively. The adoption of Vault CRM remains strong, with 27 new customer additions during the quarter and more than 150 customers now live on the platform, reinforcing Veeva Systems’ growing leadership in next-generation commercial software.

Momentum across Veeva Development Cloud remains robust. The company secured multiple enterprise biopharma wins across clinical, regulatory and safety applications while generating strong customer interest in Vault AI and Falcon at its recent European R&D and Quality Summit. These solutions are expected to improve efficiency and accelerate drug development processes, further strengthening Veeva Systems’ competitive position within the life sciences industry.

VEEV’s Zacks Rank & Stocks to ConsiderVEEV carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Key Takeaways Veeva Systems raised its FY27 revenue and EPS outlook after both metrics beat estimates in Q1.VEEV added 27 Vault CRM customers; win rate topped 80% this year, with more than 150 customers live.VEEV says that Falcon targets high-volume clinical and safety workflows; Ostro adds about $10M this year. Veeva Systems Inc. (VEEV - Free Report) used its first-quarter fiscal 2027 earnings call to frame a broader shift in strategy, arguing that its next growth phase will come from combining industry-specific software with AI agents rather than simply adding AI features to the existing products.

That message mattered as management also raised its full-year guidance after quarterly earnings and revenues both topped the Zacks Consensus Estimate, giving investors a stronger read on execution and on where Veeva Systems sees its biggest openings next.

VEEV Expands the Story Beyond SaaSChief executive officer Peter Gassner made the central point of the call clear: Veeva  Systems is moving from an industry-specific application company to an industry-specific application and AI agent company. Gassner described that as a major shift in how the company can serve life sciences customers.

Gassner said that the company is organizing its AI strategy around models, agents and applications, with Veeva Systems providing the application and agent layers for regulated life sciences work. In his framing, AI inside Vault can improve how people use software, while Falcon is designed to automate portions of work that have historically required human labor.

That emphasis gave the quarter a different tone from a standard software earnings call. The reported numbers were strong, with non-GAAP earnings of $2.24 per share beating the Zacks Consensus Estimate of $2.13. The company reported revenues of $882.95 million, which surpassed the consensus mark of $857.33 million. Also, management kept steering attention toward product architecture and long-term positioning.

Veeva Systems Lifts Full-Year TargetsChief financial officer Brian Van Wagener said that the fiscal first-quarter results exceeded guidance across all metrics, reflecting broad-based growth and profitability. Total revenues rose 16% year over year, while non-GAAP operating income climbed to $395.4 million from $349.9 million.

Management raised the fiscal 2027 revenue guidance to $3.635-$3.645 billion from its prior expectations, and projected $1.61 billion in non-GAAP operating income, with non-GAAP earnings per share of $9.05. For the fiscal second quarter, Veeva Systems expects revenues of $902 million to $905 million, and non-GAAP earnings per share of $2.21 to $2.22.

Van Wagener told Truist Securities that the macro environment looked essentially unchanged from a few months earlier. Wagener said the healthier outlook reflected continued solid demand across commercial, development and quality markets rather than any sharp improvement in external conditions.

VEEV Builds on CRM Migration WinsCommercial execution remained a key support for the story. Veeva Systems said that it added 27 Vault CRM customers in the quarter and now has more than 150 customers live on the platform.

In the Q&A, executive vice president of Strategy Paul Shawah said that recent wins with Teva and Merck KGaA were notable, though not part of the company’s fixed top-20 tracking list. Shawah said that Veeva Systems has won 10 of those large-account decisions so far compared with six for Salesforce, with four decisions left and expectations to win the majority of the remaining group.

That exchange stood out because analysts pressed management on whether prior expectations for top-20 outcomes were still intact. Shawah did not overreach, but he maintained a confident tone and backed it with an overall Vault CRM win rate above 80% this year and more than 40 migrations completed.

Veeva Systems Adds Ostro to AI MixAnother important strategic theme was the March acquisition of Ostro. Management positioned it as a compliant brand engagement platform that allows healthcare professionals and patients to ask questions and receive answers through biopharma digital properties.

Shawah told Needham that Ostro fits with Veeva Systems’ push into agentic commercial workflows and with what the company calls Commercial Evidence, or data gathered from real questions and interactions that can help biopharma clients identify barriers to getting medicines to patients.

Van Wagener said that Ostro should contribute about $10 million over the final three quarters of fiscal 2027, accounting for roughly two-thirds of the $15-million increase in the commercial subscription guidance. Wagener added that AI revenues outside Ostro should remain fairly immaterial this year.

VEEV Shows Where Falcon StartsFalcon drew the most detailed questioning from analysts and the clearest strategic responses from management. Gassner described it as Veeva Systems' first real move into digital labor, not as a toolkit for customers to build custom agents.

Gassner said that the earliest target areas are high-volume, standardized workflows such as clinical trial document intake, trial master file classification, safety case triage and regulatory correspondence. Those jobs are attractive because they are repetitive, rules-heavy and already often outsourced.

Management also offered early clues on monetization. Gassner said that Falcon will most likely be priced by document or by case, depending on the workflow, while stressing that the offering should be entirely additive because Veeva Systems does not currently sell that labor.

Veeva Systems Leaves a More Ambitious ToneThe call ended with a notably expansive posture. Gassner tied Falcon, Vault AI, Ostro and Veeva Basics into a broader effort to standardize more of life sciences work and then automate selected portions of it.

Van Wagener reinforced that tone by saying the company is still investing across Falcon, Vault AI, Ostro and its data network while preserving efficiency. The message coming out of the quarter was less about near-term margin maximization and more about building the next layer of the platform.

VEEV’s Zacks SignalsVeeva Systems currently carries a Zacks Rank #3 (Hold), with a Value Score of C, a Growth Score of B, a Momentum Score of F and a VGM Score of C. In Zacks terms, the rank points to a more balanced near-term outlook, while the style scores suggest the stock looks stronger on growth characteristics than on value or momentum. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Score framework gives the best read-through when paired with higher Zacks ranks, especially #1 and 2 (Buy) stocks with A or B style grades. The scorecard can still help frame trading style fit, but the Zacks Rank can change as earnings estimate revisions move after the quarter.

Veeva Systems (VEEV - Free Report) closed the last trading session at $172.61, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $244.88 indicates a 41.9% upside potential.

The average comprises 24 short-term price targets ranging from a low of $165.00 to a high of $340.00, with a standard deviation of $47.36. While the lowest estimate indicates a decline of 4.4% from the current price level, the most optimistic estimate points to a 97% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

But, for VEEV, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Here's Why There Could be Plenty of Upside Left in VEEVAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 0.9%.

Moreover, VEEV currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much VEEV could gain, the direction of price movement it implies does appear to be a good guide.

End-to-end safety foundation to speed case processing and enable automation

, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB is unifying its global safety operations with Veeva Safety Suite to maximize operational efficiency and scale. UCB is standardizing safety on a single platform to accelerate case processing, strengthen oversight, and streamline submissions to health authorities.

"Moving our teams onto Veeva Safety Suite is a core step in UCB's safety transformation, helping streamline global and local workflows with a single source of truth for safety data," said Jonas Maselis, head of digital technology, patient safety, UCB. "As we use automation to drive low-touch case processing, our strategic partnership with Veeva positions us well for what's next."

UCB will use Veeva Safety Suite's unified platform for end-to-end safety management, with Veeva Safety to streamline the intake, processing, and submission of adverse events and Veeva SafetyDocs to manage all safety-related content and processes. Veeva Safety Workbench will enable advanced data analysis for fast, scalable reporting, and Veeva Safety Signal will automate signal detection for better visibility and alignment across the organization. In addition, the Veeva Safety-RIM Connection will share product information automatically across regulatory and safety operations for clean and trusted data.

"UCB is building a foundation powered by Veeva Safety Suite to simplify and standardize their global pharmacovigilance function," said John Lawrie, vice president, Veeva Safety. "With a unified and connected approach, UCB is enhancing global compliance and driving advanced automation to deliver safe and effective medicines to patients."

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Elizabeth McGrane
Veeva Systems
[email protected]

SOURCE Veeva Systems

Key Takeaways Veeva's Falcon targets high-volume clinical and safety workflows with agent-based automation.AI revenues are expected to be immaterial in fiscal 2027 as the focus stays on product quality.Vault AI expands embedded automation within apps, supporting adoption and retention. Veeva Systems Inc. (VEEV - Free Report) continues to benefit from demand for life sciences cloud platforms, with steady progress in Vault CRM migrations and ongoing expansion across R&D and Quality solutions. Management’s fiscal 2027 outlook calls for mid-teens revenue growth and a stable adjusted operating margin, assuming an unchanged macro environment.

The company’s AI roadmap adds an important long-term lever. However, the near-term math remains anchored to the subscription base, not a sudden AI-driven revenues step-up.

VEEV’s Falcon Targets High-Volume Workflow AutomationFalcon is positioned as an agent layer built to take on standardized, high-volume work, with early use cases centered on clinical document intake and safety case processing. That focus matters because those tasks sit at the heart of clinical, regulatory and safety workflows, where repetitive intake and routing can consume significant staff time.

Strategically, Falcon aims to create an automation layer that can scale across multiple functions as Veeva’s footprint broadens beyond its historical commercial roots into clinical development, safety and regulatory operations.

Veeva’s Pricing Models and Adoption SignalsMonetization is still developing. Management has discussed usage-aligned approaches, such as charging per document or per case, but pricing has not been finalized. In practical terms, that creates a wide range of possible outcomes for revenue timing and magnitude, even if the product value proposition is clear.

Falcon remains early, with the company still signing initial agreements and using customer data for quality control and training agents ahead of broader rollout. For investors, the adoption curve is the key variable to watch because early deployments in narrow workflows do not automatically translate into scaled, repeatable revenues.

Image Source: Zacks Investment Research

VEEV’s Vault AI Adds Embedded Use CasesAlongside Falcon, Veeva is scaling Vault AI inside its applications. The emphasis here is on embedded capabilities that automate labor-intensive processes within existing workflows, rather than a standalone agent layer that orchestrates tasks across systems.

Falcon is designed to tackle “agentic” labor in high-volume, standardized work, while Vault AI strengthens the day-to-day utility of the underlying apps customers already use. Over time, both can raise platform stickiness by reinforcing the value of an integrated ecosystem that spans clinical, safety, regulatory, quality and commercial functions.

Veeva’s Near-Term AI Revenues Look LimitedExpectations should stay grounded. Management expects AI revenue to be immaterial in fiscal 2027 outside of Ostro, with the current priority on product quality and customer success. That sequencing keeps near-term financial results tied primarily to execution in the core subscription portfolio.

The investor takeaway is that AI is best viewed as optionality rather than a near-term driver. The focus should be on whether Falcon and Vault AI meaningfully expand workflow value and adoption over time, instead of the amount of revenue generation in fiscal 2027.

Veeva’s Competitive and Execution Risks for AIExecution risk is real on multiple fronts. CRM decisions remain competitive, and Veeva also faces platform dependencies, including Salesforce for legacy Veeva CRM and Amazon Web Services for Vault-based applications. The prior agreement with Salesforce expired on Sept. 1, 2025, and includes seat-based limits for existing customers during a wind-down period through Sept. 1, 2030, adding complexity to the transition.

For Falcon specifically, uncertainty around the adoption pace and the timing of revenue contribution remains elevated because monetization is not finalized and the rollout is still in early agreements and training. Meanwhile, cost pressures have already weighed on profitability, with gross margin contracting 220 basis points year over year to 74.9% in the fiscal first quarter as infrastructure and services costs rose.

VEEV currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

VEEV’s Milestones to Track Through FY27Key milestones are practical and measurable. First is a finalized Falcon pricing approach and whether usage-aligned models (per document or per case) translate into repeatable customer agreements. Next is the number and depth of Falcon deployments beyond the initial clinical document and safety intake workflows, along with evidence of tangible workflow impact inside Safety and clinical operations.

On the embedded side, investors should watch Vault AI's expansion within core applications and whether it improves adoption and retention across the broader platform. Finally, track whether newer product lines such as RTSM, Safety and LIMS continue scaling while management sustains its fiscal 2027 expectation for a stable adjusted operating margin.

For context within the broader Medical Info Systems group, Enovis Corporation (ENOV - Free Report) carries a Zacks Rank #2, while Evolent Health, Inc (EVH - Free Report) has a Zacks Rank #3 (Hold). That mix underscores how stock performance in the space can diverge based on execution, making Veeva’s migration progress and AI delivery the focal points through fiscal 2027.

VEEV’s Sales & EPS PictureIn fiscal 2027, VEEV is expected to experience growth of 13.9% in revenues. On the profitability front, earnings per share are expected to improve 9.5% year over year.

Image Source: Zacks Investment Research

VEEV’s Valuation PictureVEEV currently trades at a price-to-book ratio of 3.79X, well below its industry’s current level of 6.24X.

Image Source: Zacks Investment Research

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Veeva Systems (VEEV - Free Report) Veeva Systems Inc. is headquartered in Pleasanton, CA and provides industry cloud solutions for the global life sciences market. Its offerings span cloud software, data, artificial intelligence capabilities and business consulting, supporting customers from research and development through commercialization. Veeva operates as a single reportable segment and groups revenues into Commercial Solutions and R&D and Quality Solutions. 

VEEV is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. VEEV has a Growth Style Score of B, forecasting year-over-year earnings growth of 10.6% for the current fiscal year.

Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2027, while the Zacks Consensus Estimate has increased $0.10 to $8.96 per share. VEEV also boasts an average earnings surprise of +5.5%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, VEEV should be on investors' short list.

Veeva Systems (VEEV - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this provider of cloud-based software services for the life sciences industry have returned +5.2% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical Info Systems industry, to which Veeva belongs, has gained 0.6% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Veeva is expected to post earnings of $2.22 per share for the current quarter, representing a year-over-year change of +11.6%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.3%.

The consensus earnings estimate of $9.05 for the current fiscal year indicates a year-over-year change of +11.7%. This estimate has changed +3.7% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $9.9 indicates a change of +9.4% from what Veeva is expected to report a year ago. Over the past month, the estimate has changed +0.9%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Veeva is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Veeva, the consensus sales estimate of $904.07 million for the current quarter points to a year-over-year change of +14.6%. The $3.64 billion and $4.07 billion estimates for the current and next fiscal years indicate changes of +14% and +11.7%, respectively.

Last Reported Results and Surprise HistoryVeeva reported revenues of $882.95 million in the last reported quarter, representing a year-over-year change of +16.3%. EPS of $2.24 for the same period compares with $1.97 a year ago.

Compared to the Zacks Consensus Estimate of $857.33 million, the reported revenues represent a surprise of +2.99%. The EPS surprise was +5.16%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Veeva is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Veeva. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.